Editorial: Biochemical and imaging biomarkers: The search for the Holy Grail

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 8, 2010, Pages 1055-1056

  Plebani, Mario ^a,b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Abano Terme General Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; PROCALCITONIN; CALCITONIN; PROTEIN PRECURSOR;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EDITORIAL; GOLD STANDARD; HUMAN; INFECTION; INFLAMMATION; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; BLOOD; NEOPLASM; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING;

BIOLOGICAL MARKERS; CALCITONIN; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; PROTEIN PRECURSORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955444896     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.199     Document Type: Editorial

References (12)

1. Biomarkers definitions working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2000;69:89-95.
2. Ritcher W. Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imaging 2006;33:S6-10.
3. Sargent DJ, Rubinstein L, Schwartz L. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009;45:290-299
4. Van Beers BE, Vilgrain V. Biomarkers in abdominal imaging. Abdom Imaging 2009;34:663-667
5. Harry VN, Sample SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. LancetOncol 2010;ii:92-102.
6. Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et. al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med 2010;51:543-550
7. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49:113-128
8. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Bekhadi K, et. al. w18Fxfluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-1381
9. Chacko TK, Zhuang H, Nakhoda KZ, Moussavian B, Alavi A. Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection. Nucl Med Commun 2003; 24:615-624
10. Zhuang HM, Yu JQ, Alavi A. Applications of fluorodeoxyglucose- PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin N Am 2005;43: 121-134
11. Zhuang HM, Pourdehnad ES, Lambright AJ, Yamamoto M, Lanuti P, Li PD. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-1417
12. Giovanella L, Suriano S, Ricci R, Ravani P, Ceriani L. Circulating procalcitonin in aseptic carcinoma patients: a specificity study with 18F-fluorodeoxyglucose positron emission tomography/ computed tomography as benchmark Clin Chem Lab Med 2010;48.